Tag: ANGPTL8

Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 controls identifies new susceptibility loci contributing to lung cancer

Sampson, J. N. et al. Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer types. J. Natl Cancer Inst. 107, djv279 (2015). PubMed  PubMed Central  Article  CAS  Google Scholar  Bosse, Y. & Amos, C. I. A decade of GWAS results in lung cancer. Cancer Epidemiol….

Continue Reading Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 controls identifies new susceptibility loci contributing to lung cancer

Kyttaro, Lilly sign licence agreement for monoclonal antibody programme

Low magnification micrograph of the distal right coronary artery with complex atherosclerosis and luminal narrowing. Credit: Nephron / commons.wikipedia.org. Kyttaro has signed an agreement to obtain an exclusive global licence for Eli Lilly and Company’s anti-angiopoietin-like (ANGPTL) 3/8 monoclonal antibody programme to treat atherosclerotic cardiovascular disease (ASCVD). The antibody will…

Continue Reading Kyttaro, Lilly sign licence agreement for monoclonal antibody programme

Liver-specific knockdown of ANGPTL8 alters the structure of the gut microbiota in mice | Annals of Microbiology

Bacterial taxonomic profiling of the gut microbiota from between controls and sh-ANGPTL8. a Relative abundance of the top 10 abundant bacterial phyla in indicated individuals. b, c Heat map of the top 10 abundant bacterial phyla in indicated individuals (b) and T test results (c). d Relative abundance of Bacteroidetes….

Continue Reading Liver-specific knockdown of ANGPTL8 alters the structure of the gut microbiota in mice | Annals of Microbiology

The Potential of ANGPTL8 Antagonism to Simultaneously Reduce Triglyceride and Increase HDL-Cholesterol Plasma Levels

Elevated triglyceride (TG) and reduced high-density lipoprotein-cholesterol (HDL-C) plasma levels are risk factors for atherosclerosis and cardiovascular disease. Therefore, a drug that simultaneously reduces TG and increases HDL-C plasma levels has the potential to prevent and treat these diseases. Angiopoietin-like 3 (ANGPTL3) regulates plasma TG and HDL-C levels by inhibiting…

Continue Reading The Potential of ANGPTL8 Antagonism to Simultaneously Reduce Triglyceride and Increase HDL-Cholesterol Plasma Levels